CTLA4 and relapsing-remitting multiple sclerosis: In this way, Derakhshani et al. discovered that fingolimod, IFNβ-1α, and DMF could dramatically upregulate CTLA-4 expression in RRMS patients relative to treatment-naive patients, however, this effect was not observed in patients treated with GA [153].